LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) announced the completion of the 30-day post-listing stabilization period for its Global Offering, which concluded on 2 July 2026. During this window, Sinolink Securities (Hong Kong) Company Limited, acting as Stabilizing Manager, executed two key actions:

1. Overallocation • 2.13 million H Shares were over-allocated in the International Offering, equivalent to approximately 15% of the 14.19 million Offer Shares initially available under the Global Offering.

2. Full exercise of the Over-allotment Option • On 30 June 2026, the Sole Sponsor-Overall Coordinator fully exercised the Over-allotment Option for the same 2.13 million H Shares. • The shares were issued at the Offer Price of HK$96.06 per H Share, excluding related transaction costs (1.00% brokerage, 0.0027% SFC levy, 0.00565% Stock Exchange fee, and 0.00015% AFRC levy). • The issuance facilitated timely delivery to investors who had agreed to delayed settlement under the Global Offering.

No market purchases or sales of LongBio’s H Shares were conducted for stabilization purposes during the period.

The company’s board, chaired by Executive Director Dr. Liu Heng, confirmed that the stabilization measures have now concluded.